-Lactam/ -Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum -Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts | Zendy

Jesús RodríguezBaño | Zendy; M.D. Navarro | Zendy; Pilar Retamar | Zendy; Encarnación Picón | Zendy; Álvaro Pascual | Zendy

Open Access

-Lactam/ -Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum -Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts

Author(s) -

Jesús RodríguezBaño,

M.D. Navarro,

Pilar Retamar,

Encarnación Picón,

Álvaro Pascual

Publication year - 2011

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir790

Subject(s) - medicine , carbapenem , clavulanic acid , doripenem , beta lactamase inhibitors , prospective cohort study , hazard ratio , post hoc analysis , piperacillin/tazobactam , piperacillin , bacteremia , tazobactam , amoxicillin , confidence interval , antibiotics , microbiology and biotechnology , meropenem , imipenem , antibiotic resistance , pseudomonas aeruginosa , biology , bacteria , genetics

Extended-spectrum ß-lactamase-producing Escherichia coli (ESBL-EC) is an important cause of invasive infections. Alternatives to carbapenems--considered the drugs of choice--are needed because of the emergence of carbapenemase-producing enterobacteria. The efficacy of ß-lactam/ß-lactam inhibitors (BLBLI) in such infections is controversial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research